Gt Biopharma Inc Financials

GTBP

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Gt Biopharma Inc (GTBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Gt Biopharma Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.98x

For every $1 of reported earnings, Gt Biopharma Inc generates $0.98 in operating cash flow (-$12.9M OCF vs -$13.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

N/A

Free Cash Flow

N/A

Net Income

-$13.2M

YoY-73.3%

Gt Biopharma Inc reported -$13.2M in net income in fiscal year 2024. This represents a decrease of 73.3% from the prior year.

EPS (Diluted)

$-6.94

YoY-23.0%

Gt Biopharma Inc earned $-6.94 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 23.0% from the prior year.

Cash & Debt

$4.0M

YoY+266.2%

5Y CAGR+169.1%

10Y CAGR+16.5%

Gt Biopharma Inc held $4.0M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY+61.8%

Gt Biopharma Inc had 2M shares outstanding in fiscal year 2024. This represents an increase of 61.8% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$5.8M

YoY-10.3%

5Y CAGR+28.3%

Gt Biopharma Inc invested $5.8M in research and development in fiscal year 2024. This represents a decrease of 10.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GTBP Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.8M-10.3%	$6.5M-26.6%	$8.8M-8.1%	$9.6M+1877.5%	$485K-70.9%	$1.7M
SG&A Expenses	$8.6M+20.5%	$7.1M-42.9%	$12.4M-74.0%	$47.9M+663.2%	$6.3M-35.9%	$9.8M
Operating Income	-$14.4M-5.8%	-$13.6M+36.1%	-$21.3M+63.0%	-$57.5M-750.3%	-$6.8M-142.1%	$16.1M
Interest Expense	N/A	$213K+2562.5%	$8K-98.9%	$718K+123.9%	-$3.0M-41.1%	-$2.1M
Income Tax	N/A	N/A	N/A	N/A	N/A	$0
Net Income	-$13.2M-73.3%	-$7.6M+63.6%	-$20.9M+64.0%	-$58.0M-105.0%	-$28.3M+26.8%	-$38.6M
EPS (Diluted)	$-6.94-23.0%	$-5.64+71.3%	$-19.66	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$634K+74.7%	$363K-67.0%	$1.1M	N/A	$1.3M-26.7%	$1.8M+129.6%	$777K	N/A
SG&A Expenses	$2.7M+139.0%	$1.1M+38.1%	$833K	N/A	$2.3M+8.2%	$2.1M-8.3%	$2.3M	N/A
Operating Income	-$3.4M-123.5%	-$1.5M+21.7%	-$1.9M	N/A	-$3.6M+7.7%	-$3.9M-26.4%	-$3.1M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.1M-117.3%	-$1.4M-84.7%	-$776K	N/A	-$3.4M+8.1%	-$3.7M-63.7%	-$2.3M	N/A
EPS (Diluted)	$-0.83-50.9%	$-0.55-66.7%	$-0.33	N/A	$-1.53+29.5%	$-2.17-32.3%	$-1.64	N/A

GTBP Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$4.2M-70.0%	$14.1M-15.7%	$16.7M-48.0%	$32.2M+468.3%	$5.7M+1329.5%	$396K
Current Assets	$4.2M-69.9%	$14.1M-15.1%	$16.6M-48.5%	$32.2M+468.3%	$5.7M+1966.1%	$274K
Cash & Equivalents	$4.0M+266.2%	$1.1M-81.0%	$5.7M-36.8%	$9.0M+69.3%	$5.3M+18817.9%	$28K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.9M-11.0%	$6.6M+32.6%	$5.0M-51.2%	$10.3M-70.8%	$35.1M+78.1%	$19.7M
Current Liabilities	$5.9M-11.0%	$6.6M+34.3%	$4.9M-51.9%	$10.3M-70.8%	$35.1M+78.1%	$19.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.7M-122.3%	$7.5M-36.3%	$11.7M-46.4%	$21.9M+174.4%	-$29.4M-52.4%	-$19.3M
Retained Earnings	-$695.2M-1.9%	-$682.1M-1.1%	-$674.5M-3.2%	-$653.6M-9.7%	-$595.8M-5.0%	-$567.3M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	N/A	N/A	N/A	$4.2M-37.4%	$6.8M-27.1%	$9.3M-6.5%	$9.9M-29.7%	$14.1M
Current Assets	$4.3M-39.3%	$7.1M+168.0%	$2.7M-37.2%	$4.2M-37.4%	$6.8M-27.1%	$9.3M-6.3%	$9.9M-29.7%	$14.1M
Cash & Equivalents	$2.5M-51.6%	$5.2M+121.1%	$2.4M-40.1%	$4.0M-38.4%	$6.4M-30.6%	$9.2M+374.3%	$1.9M+80.7%	$1.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	N/A	N/A	$5.9M+26.6%	$4.7M+24.0%	$3.8M-18.3%	$4.6M-30.6%	$6.6M
Current Liabilities	$1.3M-42.7%	$2.3M-36.6%	$3.6M-38.4%	$5.9M+26.6%	$4.7M+24.0%	$3.8M-18.3%	$4.6M-30.6%	$6.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.0M+4.9%	$2.9M+391.9%	-$980K+41.3%	-$1.7M-179.6%	$2.1M-61.9%	$5.5M+3.7%	$5.3M-28.9%	$7.5M
Retained Earnings	-$700.8M-0.5%	-$697.5M-0.2%	-$696.0M-0.1%	-$695.2M-0.5%	-$691.5M-0.5%	-$688.0M-0.5%	-$684.3M-0.3%	-$682.1M

GTBP Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$12.9M-45.8%	-$8.9M+41.8%	-$15.2M+2.5%	-$15.6M-114.9%	-$7.3M-98.5%	-$3.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$3.7M
Investing Cash Flow	$12.9M+741.8%	-$2.0M-116.5%	$12.1M+152.7%	-$23.0M	$0-100.0%	$200K
Financing Cash Flow	$3.0M-52.5%	$6.3M+2898.2%	-$224K-100.5%	$42.3M+237.7%	$12.5M+265.7%	$3.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$3.7M-22.0%	-$3.0M-36.9%	-$2.2M+10.8%	-$2.5M+9.8%	-$2.7M+22.6%	-$3.5M+15.1%	-$4.2M-103.4%	-$2.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	$1K+200.0%	-$1K-100.0%	$7.9M+56.1%	$5.0M+953.1%	$478K
Financing Cash Flow	$977K-83.4%	$5.9M+854.1%	$616K	$0	$0	N/A	N/A	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GTBP Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-311.0%-257.2pp	-53.8%+70.9pp	-124.8%+55.6pp	-180.3%+319.5pp	-499.8%+9259.5pp	-9759.3%
Current Ratio	0.72-1.4	2.12-1.2	3.35+0.2	3.14+3.0	0.16+0.1	0.01
Debt-to-Equity	-3.53-4.4	0.89+0.5	0.43-0.0	0.47+1.7	-1.19-0.2	-1.02
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	-50.5%-10.4pp	-40.0%-17.2pp	-22.9%	N/A
Current Ratio	3.27+0.2	3.09+2.4	0.73+0.0	0.72-0.7	1.45-1.0	2.47+0.3	2.15+0.0	2.12
Debt-to-Equity	N/A	N/A	N/A	-3.53-5.8	2.22+1.5	0.68-0.2	0.87-0.0	0.89
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.72), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Protagenic Therapeutics Inc PTIX

$1.4M

Lipella Pharmaceuticals Inc LIPO

$11.8M

Salarius Pharmaceuticals Inc SLRX

$4.9M

Scinai Immunotherapeutics Ltd. SCNI

$2.6M

Virax Biolabs Group Ltd VRAX

$1.5M

Frequently Asked Questions

Is Gt Biopharma Inc profitable?

No, Gt Biopharma Inc (GTBP) reported a net income of -$13.2M in fiscal year 2024.

What is Gt Biopharma Inc's earnings per share (EPS)?

Gt Biopharma Inc (GTBP) reported diluted earnings per share of $-6.94 for fiscal year 2024. This represents a -23.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Gt Biopharma Inc's operating cash flow?

Gt Biopharma Inc (GTBP) generated -$12.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Gt Biopharma Inc's total assets?

Gt Biopharma Inc (GTBP) had $4.2M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Gt Biopharma Inc spend on research and development?

Gt Biopharma Inc (GTBP) invested $5.8M in research and development during fiscal year 2024.

How many shares does Gt Biopharma Inc have outstanding?

Gt Biopharma Inc (GTBP) had 2M shares outstanding as of fiscal year 2024.

What is Gt Biopharma Inc's current ratio?

Gt Biopharma Inc (GTBP) had a current ratio of 0.72 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Gt Biopharma Inc's debt-to-equity ratio?

Gt Biopharma Inc (GTBP) had a debt-to-equity ratio of -3.53 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Gt Biopharma Inc's return on assets (ROA)?

Gt Biopharma Inc (GTBP) had a return on assets of -311.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Gt Biopharma Inc's cash runway?

Based on fiscal year 2024 data, Gt Biopharma Inc (GTBP) had $4.0M in cash against an annual operating cash burn of $12.9M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Gt Biopharma Inc's debt-to-equity ratio negative or unusual?

Gt Biopharma Inc (GTBP) has negative shareholder equity of -$1.7M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Gt Biopharma Inc's Piotroski F-Score?

Gt Biopharma Inc (GTBP) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Gt Biopharma Inc's earnings high quality?

Gt Biopharma Inc (GTBP) has an earnings quality ratio of 0.98x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.